Thus, it is tempting to speculate that patients with lymphopenia and/ or HLA-DRB1*07 positive patients should receive 3rd line treatment with TNF-α inhibitors early in disease course without first trying 1st and 2nd line treatments. The gene discussed is TNF; the disease is lymphopenia.